Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PHOSPHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PHOSPHOTOPE.
MPI INDIUM DTPA IN 111 vs PHOSPHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical